In order to find new drugs for the treatment of AD, a large-scale study that analyzes and predicts the global database of AD treatment drugs showed that agomelatine can interact with nine AD-related targets (serotonin 2A receptor, ADORA2A, ACHE, BACE1, PTGS2, GABRG1, MAOB, SIGMAR1, and ESR1) to treat AD by repairing the serotonin, GABA, and cholinergic system [45]. The gene discussed is MAOB; the disease is Alzheimer disease.